Purple Biotech LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
G1 Execution Services, LLC and Susquehanna Securities, LLC have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Purple Biotech Ltd. ordinary shares.
NASDAQ
SCHEDULE: Purple Biotech Ltd. Ownership Filing
Intracoastal Capital LLC and associated individuals report beneficial ownership of 9.99% of Purple Biotech Ltd. ordinary shares.
NASDAQ
Susquehanna Securities, LLC has reported a 5.2% beneficial ownership stake in Purple Biotech Ltd., holding 93.95 million ordinary shares.
NASDAQ
Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Purple Biotech Ltd. through a warrant.
NASDAQ
Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Purple Biotech Ltd. ordinary shares.
NASDAQ
Lincoln Alternative Strategies LLC has reported a 9.9% beneficial ownership stake in Purple Biotech Ltd., holding 605,000 American Depositary Shares.
NASDAQ
Orca Capital AG has reported a 4.9% beneficial ownership in Purple Biotech Ltd. through American Depositary Shares, adhering to a 4.99% ownership blocker on its Series B warrants.
NASDAQ
Orca Capital AG has reported a 9.9% beneficial ownership stake in Purple Biotech Ltd. through American Depositary Shares.